Integra LifeSciences (NASDAQ:IART) Stock Price Up 6.6% – Time to Buy?

Integra LifeSciences Holdings Corporation (NASDAQ:IART) shares shot up 6.6% during mid-day trading on Thursday . The stock traded as high as $18.54 and last traded at $18.53. 176,432 shares were traded during trading, a decline of 80% from the average daily volume of 897,408 shares. The stock had previously closed at $17.38.

Analysts Set New Price Targets

A number of equities analysts have recently commented on IART shares. BMO Capital Markets started coverage on shares of Integra LifeSciences in a research note on Wednesday, July 8th. They issued a “market perform” rating and a $19.00 target price on the stock. Citigroup reaffirmed a “neutral” rating and set a $19.00 price target (up from $16.00) on shares of Integra LifeSciences in a research report on Wednesday, July 8th. Wall Street Zen downgraded Integra LifeSciences from a “strong-buy” rating to a “buy” rating in a report on Saturday, July 18th. Wells Fargo & Company raised their price objective on Integra LifeSciences from $15.00 to $18.00 and gave the company an “equal weight” rating in a research report on Thursday, July 30th. Finally, UBS Group initiated coverage on Integra LifeSciences in a research report on Tuesday, July 28th. They issued a “neutral” rating and a $19.00 target price for the company. One analyst has rated the stock with a Buy rating, five have given a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Reduce” and a consensus target price of $18.86.

Integra LifeSciences Stock Up 5.6%

The company has a debt-to-equity ratio of 1.75, a quick ratio of 2.11 and a current ratio of 3.60. The firm has a market capitalization of $1.43 billion, a P/E ratio of -203.64, a P/E/G ratio of 1.46 and a beta of 1.21. The stock has a fifty day moving average price of $17.98 and a two-hundred day moving average price of $13.76.

Integra LifeSciences (NASDAQ:IART) last announced its quarterly earnings data on Wednesday, July 29th. The life sciences company reported $0.56 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.48 by $0.08. Integra LifeSciences had a positive return on equity of 18.30% and a negative net margin of 0.44%.The firm had revenue of $418.76 million for the quarter, compared to analysts’ expectations of $417.54 million. Integra LifeSciences has set its Q3 2026 guidance at 0.530-0.610 EPS and its FY 2026 guidance at 2.400-2.500 EPS. Research analysts forecast that Integra LifeSciences Holdings Corporation will post 2.46 EPS for the current year.

Hedge Funds Weigh In On Integra LifeSciences

Several hedge funds and other institutional investors have recently made changes to their positions in IART. Rubric Capital Management LP increased its stake in shares of Integra LifeSciences by 1.3% during the fourth quarter. Rubric Capital Management LP now owns 7,753,934 shares of the life sciences company’s stock valued at $96,304,000 after acquiring an additional 100,000 shares during the period. Paradigm Capital Management Inc. NY lifted its position in Integra LifeSciences by 50.6% in the first quarter. Paradigm Capital Management Inc. NY now owns 4,012,698 shares of the life sciences company’s stock worth $37,800,000 after purchasing an additional 1,347,700 shares during the period. Invesco Ltd. boosted its stake in Integra LifeSciences by 0.9% during the 4th quarter. Invesco Ltd. now owns 3,522,839 shares of the life sciences company’s stock valued at $43,754,000 after purchasing an additional 31,931 shares in the last quarter. Dimensional Fund Advisors LP increased its position in shares of Integra LifeSciences by 9.2% during the 3rd quarter. Dimensional Fund Advisors LP now owns 3,184,726 shares of the life sciences company’s stock valued at $45,634,000 after purchasing an additional 267,134 shares during the period. Finally, State Street Corp raised its stake in shares of Integra LifeSciences by 0.8% in the 4th quarter. State Street Corp now owns 2,812,615 shares of the life sciences company’s stock worth $34,933,000 after buying an additional 21,717 shares in the last quarter. 84.78% of the stock is currently owned by institutional investors and hedge funds.

Integra LifeSciences Company Profile

Integra LifeSciences Corporation is a global medical technology company specializing in products and innovations for neurosurgery, regenerative medicine and reconstructive procedures. The company develops and markets surgical instruments, implants and advanced wound care solutions designed to support tissue repair and functional recovery. Its product portfolio includes collagen-based matrices, dural substitutes, hemostatic agents and specialized spinal and peripheral fixation devices.

Founded in 1989 and headquartered in Plainsboro, New Jersey, Integra has expanded its capabilities through targeted acquisitions and internal research efforts.